The role of MET in chemotherapy resistance.

Georgina E Wood, Helen Hockings, Danielle M Hilton, Stéphanie Kermorgant

Oncogene 2021 Mar

filter terms:

Chemotherapy remains the mainstay of treatment in the majority of solid and haematological malignancies. Resistance to cytotoxic chemotherapy is a major clinical problem and substantial research is ongoing into potential methods of overcoming this resistance. One major target, the receptor tyrosine kinase MET, has generated increasing interest with multiple clinical trials in progress. Overexpression of MET is frequently observed in a range of different cancers and is associated with poor prognosis. Studies have shown that MET promotes resistance to targeted therapies, including those targeting EGFR, BRAF and MEK. More recently, several reports suggest that MET also contributes to cytotoxic chemotherapy resistance. Here we review the preclinical evidence of MET's role in chemotherapy resistance, the mechanisms by which this resistance is mediated and the translational relevance of MET inhibitor therapy for patients with chemotherapy resistant disease.

Citation

Georgina E Wood, Helen Hockings, Danielle M Hilton, Stéphanie Kermorgant. The role of MET in chemotherapy resistance. Oncogene. 2021 Mar;40(11):1927-1941